{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:47:19Z","timestamp":1784011639886,"version":"3.55.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Over the past 20 years, the increasing use of combined therapy with immunosuppressants and biologic agents has markedly reduced the use of steroids in the management of inflammatory bowel diseases (IBD). However, medical therapy seems to promote, in the long run, carcinogenesis resulting in an increased risk of developing different types of malignancies, including lymphomas. The aim of this study was to systematically review the current incidence and prognosis of lymphoid neoplasms occurring in patients with IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Studies analyzing the incidence of lymphomas in subjects of age &amp;gt;18 years affected by IBD were included in this systematic review and meta-analysis. Studies focusing on pediatric populations, not reporting person-years of follow-up, or with a duration &amp;lt; 1 year were excluded. PubMed, Embase, Web of Science Core Collection, and Cochrane Central Register were searched from inception through January 2022. Publication bias within studies was assessed using Begg's and Egger's tests and random effects model. Quantitative results were synthesized using relative-risk meta-analysis. PRISMA guidelines were used to carry out this systematic review (PROSPERO Registration Number: CRD42023398348).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 345 studies published between 1985 and 2022, with a total of 6,17,386 patients were included in the meta-analysis. Substantial heterogeneity between studies prevented the pooling of estimates (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 97.19%). Evidence of publication bias was overall low (<jats:italic>p<\/jats:italic> = 0.1941). Patients affected by Crohn's disease (CD) were 1,86,074 (30.13%), while 2,78,876 (46.17%) were diagnosed with UC. The remaining 23.7% of cases were diagnosed with indeterminate colitis. Immunomodulators and biologic therapy were used in 24,520 (5.27%), and 17,972 (3.86%) patients, respectively. Reported incidence rates for lymphoma in IBD ranged from 0.0\/100,000 person\/years (py) (95% CI 0.0\u20133.7\/100,000) to 89\/100,000 py (95% CI 36\u2013160\/100,000). Reported incidence rates of lymphoma in CD ranged from 0.0\/100,000 py (95% CI 0.0\u20133.7\/100,000) to 91\/100,000 py (95% CI 18\u2013164\/100,000). For UC, the incidence rate ranged from 0.0\/100,000 py (95% CI 0.0\u20133.7\/100,000) to 95\/100,000 py (95% CI 0\u2013226\/100,000). Male-to-female ratio was ~4:1. Therapy with immunomodulators was directly associated with an increased incidence of lymphoma (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001). Evidence of publication bias was overall low (<jats:italic>p<\/jats:italic> = 0 .1941).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The evidence arising from this study highlights a correlation between the use of immunomodulators and subsequent lymphoma development. Combined multidisciplinary approach and long-term follow-up are warranted in order to decrease mortality deriving from the coexistence of both conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>Identifier: CRD42023398348.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1172634","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:07:38Z","timestamp":1683090458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence of lymphomas in inflammatory bowel disease: report of an emblematic case, systematic review, and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Maria Francesca","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Diddoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Castagneto-Gissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","article-title":"The relationship between infliximab treatment and lymphoma in Crohn's disease","volume":"117","author":"Bickston","year":"1999","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/j.1572-0241.2000.02316.x","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"95","author":"Loftus EV","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2015.03.008","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ecco-jcc\/jjy065","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fphar.2019.00247","article-title":"Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies","volume":"10","author":"Ferraro","year":"2019","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"B19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jrsm.1411","year":"2020","journal-title":"Res Syn Meth"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch16","article-title":"Special Topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"B22","unstructured":"DeanAG\n            SullivanKM\n            SoeMM\n          25503279OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version.2013"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"B24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.bdj.4809877","article-title":"Further statistics in dentistry. Part 8: systematic reviews and meta-analyses","volume":"194","author":"Petrie","year":"2003","journal-title":"Br Dental J."},{"key":"B26","unstructured":"MedCalc Statistical Software version 19,.2.6 (MedCalc Software bv, Ostend, Belgium2020"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S693","DOI":"10.14309\/00000434-201210001-01710","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for ulcerative colitis: a nationwide 10-year retrospective cohort from the veterans affairs healthcare system","volume":"107","author":"Abbas","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4&lt;854::AID-CNCR1073&gt;3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/ecco-jcc\/jjw048","article-title":"Inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case-control IG-IBD study","volume":"10","author":"Biancone","year":"2016","journal-title":"J Crohns Colitis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ibd\/izz155","article-title":"Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study","volume":"26","author":"Biancone","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.dld.2016.07.008","article-title":"Total and cancer mortality in a cohort of ulcerative colitis and Crohn's disease patients: the Florence inflammatory bowel disease study, 1978\u20132010","volume":"48","author":"Caini","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1590\/S0004-28032013000200021","article-title":"Intestinal and extraintestinal neoplasia in patients with inflammatory bowel disease in a tertiary care hospital","volume":"50","author":"Campos","year":"2013","journal-title":"Arq Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10620-010-1430-z","article-title":"Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population","volume":"56","author":"Chiorean","year":"2011","journal-title":"Dig Dis Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"de Francisco","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"B37","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J","article-title":"Extraintestinal cancers in inflammatory bowel disease","volume":"56","author":"Greenstein","year":"1985","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1365-2036.2004.01858.x","article-title":"Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark","volume":"19","author":"Jess","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjx040","article-title":"Cancer risk in the early stages of inflammatory bowel disease in korean patients: a nationwide population-based study","volume":"11","author":"Jung","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3109\/00365521.2013.846402","article-title":"Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland","volume":"48","author":"Jussila","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","article-title":"Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"34","author":"Khan","year":"2017","journal-title":"Drugs Aging"},{"key":"B44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjz204","article-title":"Lack of increased risk of lymphoma by thiopurines or biologics in japanese patients with inflammatory bowel disease: a large-scale administrative database analysis","volume":"14","author":"Kobayashi","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S-253","DOI":"10.1016\/S0016-5085(12)60954-8","article-title":"Sa1247 Low risk of lymphoma in inflammatory bowel diseases in Western Hungary. Results from a population-based incident cohort","volume":"142","author":"Lakatos","year":"2012","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000447259","article-title":"Malignancies in patients with inflammatory bowel disease: a single-centre experience","volume":"94","author":"Madanchi","year":"2016","journal-title":"Digestion"},{"key":"B48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1023\/A:1008988215904","article-title":"Crohn's disease and cancer risk (Denmark)","volume":"11","author":"Mellemkjaer","year":"2000","journal-title":"Cancer Causes Control"},{"key":"B49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000273784","article-title":"Malignancy in Crohn's disease: incidence and clinical characteristics in Japan","volume":"81","author":"Mizushima","year":"2010","journal-title":"Digestion"},{"key":"B50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/gast.2000.16487","article-title":"Hodgkin's disease risk is increased in patients with ulcerative colitis","volume":"119","author":"Palli","year":"2000","journal-title":"Gastroenterology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/jgh.15880","article-title":"Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: a longitudinal cohort analysis from northern India","volume":"37","author":"Ranjan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in inflammatory bowel disease: frequency, incidence and risk factors-results from the Swiss IBD cohort study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ijc.30183","article-title":"Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort","volume":"139","author":"van den Heuvel","year":"2016","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gastrohep.2009.09.002","article-title":"Trastornos linfoproliferativos en una unidad de enfermedad inflamatoria intestinal [Lymphoproliferative disorders in an inflammatory bowel disease unit]","volume":"33","author":"Van Domselaar","year":"2010","journal-title":"Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S1542-3565(04)00543-9","article-title":"Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County","volume":"2","author":"Winther","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/jgh.12189","article-title":"Cancer risk in Japanese Crohn's disease patients: investigation of the standardized incidence ratio","volume":"28","author":"Yano","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1182\/blood-2018-99-110615","article-title":"Inflammatory bowel disease and Hodgkin's lymphoma: two new observations","volume":"132","author":"Tazi Mezalek","year":"2018","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/cancers15030750","article-title":"Clinical presentation, management, and evolution of lymphomas in patients with inflammatory bowel disease: an ENEIDA registry study","volume":"15","author":"Guerra","year":"2023","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"10103","DOI":"10.3748\/wjg.v22.i46.10103","article-title":"Thiopurines and inflammatory bowel disease: current evidence and a historical perspective","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/ajg.2009.745","article-title":"Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study","volume":"105","author":"Armstrong","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaut.2017.02.001","article-title":"Impact of anti-TNF therapy on NK cells function and on immu-nosurveillance against B-cell lymphomas","volume":"80","author":"Nocturne","year":"2017","journal-title":"J Autoimmun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/ibd\/izaa065","article-title":"Propagation of EBV-driven lymphomatous transformation of peripheral blood B cells by immu-nomodulators and biologics used in the treatment of inflammatory bowel disease","volume":"26","author":"Levhar","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ecco-jcc\/jjw221","article-title":"Five-year safety data from ENCORE, a European observational safety registry for adults with crohn's disease treated with infliximab [Remicade\u00ae] or conventional therapy","volume":"11","author":"D'Haens","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"733992","DOI":"10.3389\/fcimb.2022.733992","article-title":"The gut microbiota in inflammatory bowel disease","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B69","first-page":"3533","article-title":"Effect of high-risk diets for colon carcinogenesis on intestinal mucosal and bacterial beta-glucuronidase activity in F344 rats","volume":"37","author":"Reddy","year":"1977","journal-title":"Cancer Res"},{"key":"B70","first-page":"331","article-title":"Effect of beta-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats","volume":"42","author":"Takada","year":"1982","journal-title":"Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0027-5107(01)00176-2","article-title":"Impact of bacteria in dairy products and of the intestinal microflora on the genotoxic and carcinogenic effects of heterocyclic aromatic amines","author":"Knasm\u00fcller","year":"2001","journal-title":"Mutat Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"117955492110241","DOI":"10.1177\/11795549211024197","article-title":"Emerging roles for the gut microbiome in lymphoid neoplasms","volume":"15","author":"Shi","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-Z","article-title":"Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma","volume":"338","author":"Wotherspoon","year":"1991","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/1096-9896(2000)9999:9999&lt;::AID-PATH619&gt;3.0.CO;2-H","article-title":"Outbred mice with long-term Helicobacter felis infection develop both gastric lymphoid tissue and glandular hyperplastic lesions","volume":"191","author":"Ferrero","year":"2000","journal-title":"J Pathol"},{"key":"B75","first-page":"217","article-title":"MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma","volume":"147","author":"Enno","year":"1995","journal-title":"Am J Pathol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S0140-6736(88)90867-7","article-title":"Evidence for an infective cause of childhood leukaemia: comparison of a Scottish new town with nuclear reprocessing sites in Britain","volume":"2","author":"Kinlen","year":"1988","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/2159-8290.CD-15-0892","article-title":"Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility","volume":"5","author":"Mart\u00edn-Lorenzo","year":"2015","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1172634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:07:46Z","timestamp":1683090466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1172634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":77,"alternative-id":["10.3389\/fmed.2023.1172634"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1172634","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1172634"}}